Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "Bernardino Clavo, MD"
10
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT04299893
Recruiting
Phase 2/3
Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)
Bernardino Clavo, MD, PhD
ClinicalTrials.gov · CTIS (EMA)
NCT04299893
Recruiting
Phase 2/3
Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)
Bernardino Clavo, MD, PhD
NCT01868906
Terminated
Phase 2
FMISO-PET in Brain Tumors and SCS Effect
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT01868906
Terminated
Phase 2
FMISO-PET in Brain Tumors and SCS Effect
Bernardino Clavo, MD, PhD
NCT03282695
Completed
Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT03282695
Completed
-
Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Pr...
Bernardino Clavo, MD, PhD
NCT03660657
Terminated
Phase 2/3
Ozone Therapy in Refractory Ischemic Heart Disease.
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT03660657
Terminated
Phase 2/3
Ozone Therapy in Refractory Ischemic Heart Disease.
Bernardino Clavo, MD, PhD
NCT05417737
Active Not Recruiting
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT05417737
Active Not Recruiting
-
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone T...
Bernardino Clavo, MD, PhD
NCT06706544
Recruiting
Phase 2/3
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
Bernardino Clavo, MD, PhD
ClinicalTrials.gov · CTIS (EMA)
NCT06706544
Recruiting
Phase 2/3
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-in...
Bernardino Clavo, MD, PhD
NCT06799351
Recruiting
Phase 2/3
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT06799351
Recruiting
Phase 2/3
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the...
Bernardino Clavo, MD, PhD
NCT06816095
Recruiting
Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT06816095
Recruiting
-
Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor P...
Bernardino Clavo, MD, PhD
NCT07259681
Recruiting
Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT07259681
Recruiting
-
Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls V...
Bernardino Clavo, MD, PhD
NCT07325851
Recruiting
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.
Bernardino Clavo, MD, PhD
ClinicalTrials.gov
NCT07325851
Recruiting
-
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone T...
Bernardino Clavo, MD, PhD
Result Breakdown
Status
Recruiting
6 (60%)
Terminated
2 (20%)
Completed
1 (10%)
Active, not recruiting
1 (10%)
Phase
Not Specified
5 (50%)
Phase 2/3
4 (40%)
Phase 2
1 (10%)
Top Conditions
Radiation Toxicity
3 (30%)
Chemotherapy-induced Peripheral Neuropathy
2 (20%)
Chronic Pain
2 (20%)
Show 7 more
Top Sponsors
Bernardino Clavo, MD, PhD
10 (100%)
Fundación Canaria Instituto de Investigación Sanitaria de Canarias
7 (70%)
Council of Gran Canaria
6 (60%)
Show 7 more
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease